Zoetis vaccine launched to protect against PCV2 and M. hyo

A new one-bottle, one-dose bivalent vaccine that helps protect pigs against the effects of both porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) has been launched by Zoetis.

Called Suvaxyn Circo+MH RTU, the vaccine provides active immunisation against the economically important diseases caused by PCV2 and enzootic pneumonia.

“Respiratory disease from M. hyo, and the effects of PCV2, can be devastating to pig herds through reduced growth rates, poor feed efficiency, increased mortality and extended time to market,” said Zoetis UK pig and poultry business unit director, Ben Lacey (pictured above). “That is why we let science lead the way in developing an effective vaccine in one convenient bottle that is fit for the 21st Century.

“This is a true bivalent vaccine built from the ground up and not just two existing products mixed together. Aspects of human vaccine technology have also been applied to the manufacturing process.”

The company also reported that clinical trials have shown that Suvaxyn Circo+MH RTU reduces faecal shedding caused by PCV2 infection, as well as reducing the viral load in blood and lymphoid tissues.

“It also reduces lung lesions caused by M. hyo infection,” said Zoetis. ”This protection is achieved from a single 2ml dose that can be given from three weeks of age. The onset of immunity to both PCV2 and M. hyo is fully effective three weeks after vaccination.

“Additional benefits of using one-shot vaccination include reducing stress for the pigs and decreasing labour time required for vaccination, as only a single injection is required.”

Get Our E-Newsletter - Pig World's best stories in your in-box twice a week
Will be used in accordance with our Privacy Policy
Share.

About The Author